Associate
Celltrion, Inc.
Celltrion is a global biopharmaceutical leader specializing in the treatment of autoimmune diseases, including inflammatory bowel disease (IBD). The company pioneered the commercialization of the world’s first antibody biosimilar and continues to provide innovative solutions for IBD treatment.
Celltrion’s flagship infliximab biosimilar, Remsima®, has revolutionized the treatment of Crohn’s disease and ulcerative colitis and is widely used across key global markets. In addition, Celltrion has developed Zymfentra™, a subcutaneous infliximab formulation specifically designed for the maintenance treatment of IBD. Zymfentra™ offers patients a more convenient and effective treatment option, enhancing their quality of life through sustained therapeutic efficacy.
Celltrion remains committed to advancing access and innovation in IBD therapy through ongoing research into next-generation biologics and expanding therapeutic options, striving to deliver patient-centered healthcare solutions worldwide.